Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma
NCT06179888Phase 2Suspended
- Sponsor
- National Cancer Institute
- Start
- Aug 2024
- Primary completion
- Mar 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iberdomide in multiple myeloma (MM) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Incidence of dose-limiting toxicities at 3 months and Progression-free survival up to 4 years. Started Aug 2024; status: suspended.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06179888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06179888.